-
Is use of depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City) linked to risk of toxic shock syndrome? Contraceptive Technology Update Editorial Advisory Board member Felicia Stewart, MD, adjunct professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California San Francisco and co-director of the Center for Reproductive Health Research & Policy, tackles this question.
-
Reaching teens with up-to-date information is an important part of providing family planning and sexually transmitted disease (STD) counseling. Consider these web sites:
-
Rewind to 1998: The Centers for Disease Control and Prevention (CDC) launches its plan to eliminate syphilis in the United States, with the goals of reducing the total number of primary and secondary syphilis cases to 1,000 or fewer 0.4 cases per 100,000 people and increasing the number of syphilis-free counties to 90% by 2005.
-
Ready to update your knowledge on family planning issues and network with fellow clinicians? Take advantage of upcoming fall conferences, all aimed at family planning providers.
-
The young woman sitting in front of you is in good health and says she would like to use a birth control pill. Which pill do you prescribe?
-
As you check the chart of a new patient, you note that she has previously experienced nausea on birth control pills, but cant remember the brand name of her prescribed oral contraceptive (OC). She would like to re-establish pill use. Which OC will you suggest?
-
On Aug. 26, the U.S. Food and Drug Administration (FDA) announced that it would indefinitely postpone its decision to allow nonprescription status for the emergency contraceptive pill Plan B popularly known as the morning-after pill.
-
As you review the list of contraceptive options available at your family planning facility with your next female patient, which one most likely will receive the nod from her?
-
More women are choosing long-term birth control through use of intrauterine contraception, say participants in the 2005 Contraceptive Technology Update Contraception Survey.
-
Rewind to November 2004: the Food and Drug Administration (FDA) announces the addition of a black box warning to the labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City and MedroxyPROGESTERone Injection, Teva Pharmaceuticals USA, North Wales, PA).
